---

MALIGNANT OTITIS EXTERNA (Necrotizing Otitis Externa)

---

1. DEFINITION

The term "malignant" was coined by Chandler (1968) — not to imply neoplasia, but to emphasize its aggressive and life-threatening nature. Many modern authors prefer "necrotizing" as it is more pathologically accurate. (Scott-Brown's Otorhinolaryngology, 8th ed.)

---

2. EPIDEMIOLOGY

---

3. ETIOPATHOLOGY

3a. Predisposing Factors

┌─────────────────────────────────────────────────────────────────────┐
│                    PREDISPOSING CONDITIONS                           │
│                                                                      │
│   Diabetes Mellitus (most common) ─────────────────────────────┐    │
│   • Microangiopathy → reduced tissue perfusion                  │    │
│   • Impaired neutrophil function (chemotaxis, phagocytosis)     │    │
│   • Impaired T-cell mediated immunity                           ├──► SUSCEPTIBILITY │
│                                                                  │    │
│   Immunocompromise                                               │    │
│   • HIV/AIDS (CD4 <200)                                         │    │
│   • Post-chemotherapy, organ transplant                         │    │
│   • Long-term corticosteroid therapy                            │    │
│   • Hematological malignancies (leukemia, lymphoma)             ┘    │
└─────────────────────────────────────────────────────────────────────┘

3b. Causative Organisms

• Primary: Pseudomonas aeruginosa — a Gram-negative, oxidase-positive bacillus
  • Produces exotoxin A (inhibits protein synthesis), elastase, phospholipase C, pyocyanin
  • These enzymes destroy cartilage, soft tissue, and bone
  • Forms biofilms resistant to antibiotics and host immunity
• Fungal (rare): Aspergillus fumigatus / Aspergillus flavus — seen in non-diabetic immunocompromised (HIV, post-transplant). More aggressive, worse prognosis (Cummings, 7th ed., p. 2007)
• Others: Staphylococcus aureus, Klebsiella, Proteus mirabilis (rare)

3c. Pathogenesis

┌─────────────────────────────────────────────────────────────────────────────────┐
│                        PATHOGENESIS OF MOE                                       │
│                                                                                  │
│  P. aeruginosa colonizes                                                         │
│  external auditory canal (EAC)                                                   │
│          │                                                                       │
│          ▼                                                                       │
│  Impaired local immunity (diabetic microangiopathy, earwax changes)              │
│          │                                                                       │
│          ▼                                                                       │
│  Infection of skin of EAC → Perichondritis → Chondritis                         │
│          │                                                                       │
│          ▼                                                                       │
│  Spread through FISSURES OF SANTORINI                                            │
│  (defects in cartilaginous floor of EAC)                                         │
│          │                                                                       │
│          ├──────────────────────────────────────────────────┐                   │
│          ▼                                                   ▼                   │
│  PAROTID space / TMJ                         MASTOID / MIDDLE EAR               │
│          │                                            │                         │
│          ▼                                            ▼                         │
│  Infratemporal fossa                     SKULL BASE OSTEOMYELITIS               │
│          │                                            │                         │
│          └──────────────────┬─────────────────────────┘                         │
│                             ▼                                                    │
│                   CRANIAL NERVE INVOLVEMENT                                      │
│                   (VII → IX → X → XI → XII)                                     │
│                             │                                                    │
│                             ▼                                                    │
│          Sigmoid sinus thrombosis / Meningitis / Brain abscess                  │
│                             │                                                    │
│                             ▼                                                    │
│                           DEATH                                                  │
└─────────────────────────────────────────────────────────────────────────────────┘

3d. Role of Diabetes in Pathogenesis

• Microangiopathy → reduced oxygen delivery → impaired healing
• Hyperglycemia → acidic tissue environment → Pseudomonas thrives
• Reduced cerumen secretion (antibacterial barrier lost)
• Neutrophil dysfunction → reduced phagocytosis and oxidative burst
• ESR >100 mm/hr common, correlating with disease activity (Hazarika)

---

4. CLINICAL FEATURES

4a. Symptoms (by Stage)

Stage I — Early (Soft Tissue Stage)

• Severe, unrelenting otalgia (disproportionate to local findings — hallmark)
• Otorrhoea — purulent, foul-smelling
• Decreased hearing (CHL due to debris)
• Granulation tissue at osseocartilaginous junction (floor of EAC at 6 o'clock position) — pathognomonic clinical finding
• Tenderness anterior to tragus, extending to TMJ

Stage II — Bone Invasion (Osteomyelitis Stage)

• All above features + worsening
• Facial nerve palsy (VII) — most common CN involved (50–67% of cases); seen at stylomastoid foramen involvement
• TMJ involvement → trismus, jaw pain
• Parotid gland involvement → parotid swelling

Stage III — Skull Base / Intracranial Stage

• Glossopharyngeal (IX), Vagus (X), Accessory (XI) — jugular foramen syndrome (Vernet's syndrome)
• Hypoglossal (XII) — tongue deviation
• Abducens (VI) — diplopia (Gradenigo's extension)
• Sigmoid sinus thrombosis
• Meningitis, epidural abscess, brain abscess
• Septicaemia → multiorgan failure

4b. Signs

"The tympanic membrane is often intact in MOE — this distinguishes it from chronic otitis media with bone erosion." (Scott-Brown's, 8th ed.)

---

5. INVESTIGATIONS

5a. Laboratory

5b. Imaging

CT Scan (Investigation of Choice for Bone)

• Shows erosion of cortical bone of EAC, mastoid, skull base
• Identifies soft tissue extension, parapharyngeal involvement
• Limitations: Bone changes lag behind clinical improvement — not ideal for monitoring

MRI (Best for Soft Tissue / Intracranial Extension)

• T1: Low signal in marrow (osteomyelitis)
• T2: High signal in soft tissue edema/abscess
• Gadolinium-enhanced T1: Shows extent of granulation tissue, dural involvement, cavernous sinus thrombosis
• "Ink smudge" pattern on T2 — characteristic of Pseudomonas granulation tissue (Harrison's 21st ed., p. 4839)

---

---

Radionuclide Scanning

"Gallium scan is the gold standard for monitoring treatment response in MOE — it normalises with resolution of infection, unlike the bone scan which may remain positive for months." (Cummings, 7th ed.)

PET-CT (Recent Advance)

• 18F-FDG PET-CT has emerged as superior to gallium scintigraphy for monitoring
• High sensitivity (~100%) and specificity (~93%)
• Guides duration of antibiotic therapy (Rubin Grandis, 2020; Laryngoscope)

---

6. DIAGNOSTIC CRITERIA

• Elderly diabetic
• Severe persistent otalgia
• Purulent otorrhoea
• Granulation tissue in EAC
• Growth of P. aeruginosa
• Failure to respond to conventional treatment

---

7. STAGING (Chandler's / Cohen's Classification)

Facial nerve involvement correlates with Stage III; involvement of lower cranial nerves (IX–XII) indicates Stage IV in many classifications (Stell & Maran, 5th ed.)

---

8. DIFFERENTIAL DIAGNOSIS

---

9. MANAGEMENT

MANAGEMENT FLOWCHART

┌────────────────────────────────────────────────────────────────┐
│              SUSPECTED MALIGNANT OTITIS EXTERNA                 │
│    (Severe otalgia + Granulation in EAC + DM/Immunocomp.)      │
└──────────────────────────────┬─────────────────────────────────┘
                               │
               ┌───────────────▼───────────────┐
               │         CONFIRM DIAGNOSIS      │
               │  • Ear swab C&S               │
               │  • Blood glucose, ESR, CRP    │
               │  • CT temporal bone / MRI     │
               │  • Tc-99 bone scan / PET-CT   │
               └───────────────┬───────────────┘
                               │
               ┌───────────────▼───────────────┐
               │       HOSPITALIZATION          │
               │  (All cases — initially)       │
               └───────────────┬───────────────┘
                               │
        ┌──────────────────────┼────────────────────────┐
        ▼                      ▼                         ▼
 MEDICAL                SURGICAL                 ADJUNCTIVE
 MANAGEMENT             MANAGEMENT               MEASURES
 (Primary)              (If needed)
        │                      │                         │
        ▼                      ▼                         ▼
 • IV Ciprofloxacin      • Debridement EAC         • Diabetic control
   (anti-pseudomonal)    • Biopsy (r/o Ca)         • Hyperbaric O₂
 • ± Aminoglycoside      • Rarely: mastoidectomy   • Nutritional support
 • Topical treatment     • Facial nerve            • Pain management
 • Duration 6–8 wks       decompression (rarely)  • Gallium scan monitoring
        │
        ▼
  MONITOR RESPONSE
  • ESR/CRP weekly
  • Gallium scan / PET-CT
  • Symptoms regression
        │
   ┌────┴────┐
   ▼         ▼
IMPROVED  NOT IMPROVED
Step down   Switch antibiotics
oral Cipro  Surgical debridement
6–12 wks   Hyperbaric O₂

---

9a. Medical Management (Mainstay)

First-Line Antibiotic Therapy

For Fungal MOE (Aspergillus)

• Voriconazole — drug of choice (200 mg BD)
• Liposomal Amphotericin B — alternative
• Duration: minimum 12–16 weeks (Harrison's, 21st ed.)

Topical Therapy

• Ciprofloxacin ear drops (0.3%) — adjunctive
• Aural toilet and regular cleaning of EAC debris
• Acetic acid 2% drops (not sufficient alone; adjunct only)

9b. Control of Diabetes

• Tight glycaemic control is critical — improves neutrophil function, tissue perfusion, and response to antibiotics
• IV insulin infusion in acute phase; target blood glucose 6–10 mmol/L
• HbA1c must be optimized during prolonged antibiotic therapy

9c. Surgical Management

"Radical surgery is no longer recommended as the primary modality; aggressive medical therapy with prolonged anti-pseudomonal antibiotics has replaced the surgical approach." (Zakir Hussain, ENT Surgery, 3rd ed.)

9d. Hyperbaric Oxygen Therapy (HBO)

• Mechanism: Increases tissue pO₂ in hypoxic bone → enhanced neutrophil bactericidal activity → improved antibiotic penetration
• Indication: Refractory cases, multiple cranial nerve palsies, failed first-line antibiotics
• Protocol: 2.0–2.4 atmospheres, 100% oxygen, 90 min sessions, 30–60 sessions
• Evidence: Case series show benefit in refractory and fungal MOE (Mader, 1989; Ress, 2003)
• Not universally available; limited to tertiary centres (Scott-Brown's, 8th ed.)

9e. Monitoring Treatment Response

MONITORING PROTOCOL FOR MOE
━━━━━━━━━━━━━━━━━━━━━━━━━━━
Weekly:
  → ESR, CRP, blood glucose
  → Clinical assessment (pain, otorrhoea, granulation)

Every 4 weeks:
  → MRI (soft tissue response)
  → CT if bone progression suspected

End of therapy:
  → Gallium-67 scan / PET-CT
  → ONLY discontinue antibiotics if scan NORMALIZES
  → ESR should return to near-normal (<30 mm/hr)
━━━━━━━━━━━━━━━━━━━━━━━━━━━

---

10. COMPLICATIONS

---

11. PROGNOSIS

• Recurrence rate: 9–27% even after apparent cure — long-term follow-up essential (Cummings)
• Facial nerve palsy recovery: Partial in 50–60%; full recovery uncommon once palsied (Dhingra, 7th ed.)

---

12. RECENT ADVANCES (RGUHS-Relevant)

12a. Diagnostic Advances

• 18F-FDG PET-CT: Now considered superior to Gallium-67 scanning for both initial staging and monitoring treatment response. Standardised Uptake Value (SUV) can be quantified (Stern Ginat et al., Laryngoscope 2020)
• Diffusion-weighted MRI (DWI): Detects subtle intracranial complications earlier than conventional MRI
• PCR-based pathogen identification: Faster than conventional culture; identifies resistant genes (e.g., OXA-type carbapenemases in Pseudomonas)

12b. Therapeutic Advances

• Oral ciprofloxacin step-down therapy: Validated for stable patients after initial IV therapy; equivalent outcomes to prolonged IV (Grandis et al.)
• Ceftolozane-tazobactam / Ceftazidime-avibactam: New beta-lactam/beta-lactamase inhibitor combinations for MDR Pseudomonas in MOE (FDA approved; Infectious Diseases Society of America 2022)
• Voriconazole monotherapy for Aspergillus MOE: replaced Amphotericin B as first-line (ESCMID 2022 guidelines)
• Anti-biofilm strategies: Gallium nitrate (disrupts Pseudomonas iron metabolism and biofilm) — experimental
• Immunotherapy adjuncts: G-CSF (granulocyte colony-stimulating factor) in neutropenic MOE — investigational

12c. Fungal MOE (Emerging Entity)

• Increasing incidence with rising immunosuppression (post-COVID, biologics, immunotherapy)
• Aspergillus MOE: earlier intracranial spread, worse prognosis, does NOT respond to ciprofloxacin
• Voriconazole TDM (therapeutic drug monitoring) essential for dosing (Sohal et al., 2021)

---

13. SUMMARY TABLE

---

14. REFERENCES

1. Harrison's Principles of Internal Medicine, 21st Edition — p. 4839 (Pseudomonas and MOE)
2. Scott-Brown's Otorhinolaryngology, Head and Neck Surgery, 8th Edition — Chapter on Otitis Externa
3. Cummings Otolaryngology — Head and Neck Surgery, 7th Edition — Chapter 137: Infections of the External Ear
4. Dhingra PL — Diseases of Ear, Nose and Throat, 7th Edition — Chapter 5: Diseases of External Ear
5. Stell & Maran's Head and Neck Surgery and Oncology, 5th Edition
6. Hazarika P — Textbook of Ear Nose and Throat Diseases, 12th Edition
7. Zakir Hussain — ENT Surgery (Practical ENT), 3rd Edition
8. Chandler JR (1968) — Original description of MOE; Laryngoscope 78:1257–1294
9. Grandis JR et al. (1995) — Ciprofloxacin in MOE; Laryngoscope
10. Stern Ginat D et al. (2020) — PET-CT in MOE monitoring; Laryngoscope
11. ESCMID/ECMM/ERS 2022 Guidelines — Aspergillosis management

---

RGUHS Examination Tip: MOE is a high-yield topic in ENT theory exams. Key points to always include: (1) Fissures of Santorini as spread pathway, (2) Granulation at osseocartilaginous junction as pathognomonic sign, (3) Gallium scan for monitoring (not CT), (4) Ciprofloxacin as DOC, (5) Staging by CN involvement, (6) PET-CT as a recent advance replacing Gallium scanning.